Black Friday Get Elite for just $149.00 Claim Now

Nexentis Technologies Inc.

Contributing Author

Recent Articles by Nexentis Technologies Inc.

Nov-05	Nexentis Announces Reverse Stock Split NXTS -13.24% GlobeNewswire
Oct-29	Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz NXTS GlobeNewswire
Oct-26	Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage NXTS +7.27% GlobeNewswire
Oct-12	Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis NXTS -11.86% GlobeNewswire
Oct-07	Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud NXTS -22.30% GlobeNewswire
Sep-24	Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board NXTS GlobeNewswire
Sep-23	Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery NXTS GlobeNewswire
Jul-28	Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign NXTS -7.19% GlobeNewswire
Jul-07	Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative NXTS GlobeNewswire
Jun-29	Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation - Significant Premium to Initial Investment NXTS -6.60% GlobeNewswire
Jun-22	Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery NXTS +155.91% GlobeNewswire
Jun-17	Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases NXTS -8.25% GlobeNewswire
May-18	Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development NXTS +10.76% GlobeNewswire
May-13	Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone NXTS GlobeNewswire
May-05	Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX's Algorithm Platform MITOLINE NXTS GlobeNewswire
Mar-13	Nexentis Technologies Inc. Launches New Corporate Website, Showcasing Innovative AI-Driven Biotech Platform NXTS GlobeNewswire

Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)